Asco 2019 – KRAS chase heats up with Amgen data
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
Affimed turns its back on T-cell recruitment
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Astra’s first attempt fails, but there’s no giving up on KRAS
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
In sticking to the knitting has Array given up too much?
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
JP Morgan 2019 day three roundup – Abbvie rekindles the takeover flame
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Esmo 2018 – Accelerated approval looks more doubtful for Mirati
The company's stock slumped on disappointing data from its sitravatinib-Opdivo combo lung cancer study, and on news that the group will will need to carry out a…
Mid-cap investors see Eastern promise in the third quarter
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.